These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26535999)

  • 21. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation.
    Yabu JM; Higgins JP; Chen G; Sequeira F; Busque S; Tyan DB
    Transplantation; 2011 Feb; 91(3):342-7. PubMed ID: 21116220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of C1q fixing donor-specific antibodies on renal transplant outcome.
    Baranwal AK; Goswami S; Agarwal SK; Kaur G; Mehra NK
    Scand J Immunol; 2021 Jul; 94(1):e13048. PubMed ID: 33914934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients.
    Fichtner A; Süsal C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Opelz G; Tönshoff B
    Pediatr Nephrol; 2016 Jul; 31(7):1157-66. PubMed ID: 26928311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
    Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
    Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study.
    Moktefi A; Parisot J; Desvaux D; Canoui-Poitrine F; Brocheriou I; Peltier J; Audard V; Kofman T; Suberbielle C; Lang P; Rondeau E; Grimbert P; Matignon M
    Transpl Int; 2017 Mar; 30(3):277-287. PubMed ID: 27992962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation.
    Ciurea SO; Thall PF; Milton DR; Barnes TH; Kongtim P; Carmazzi Y; López AA; Yap DY; Popat U; Rondon G; Lichtiger B; Aung F; Afshar-Kharghan V; Ma Q; Fernández-Viña M; Champlin RE; Cao K
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1392-8. PubMed ID: 25985919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of C1q-fixing donor-specific antibodies after kidney transplantation.
    Thammanichanond D; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Worawichawong S; Jirasiritham S; Kitpoka P
    Transplant Proc; 2014; 46(2):368-71. PubMed ID: 24655965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
    Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
    Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.
    Brugière O; Roux A; Le Pavec J; Sroussi D; Parquin F; Pradère P; Dupin C; Bunel V; Mourin G; Jebrak G; Dauriat G; Castier Y; Mordant P; Lortat-Jacob B; Jean-Baptiste S; Mal H; Suberbielle C; Gautreau C; Caillat-Zucman S; Cazes A; Thabut G; Taupin JL
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
    Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
    Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
    J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
    Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
    J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
    Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
    Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.